Ro currently states that Medicaid patients are not eligible for its weight-loss program
Lancet Title: Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (Surmount-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial
Sources Consulted Secondary data for the market study was gathered from multiple credible sources, including: Government databases, regulatory bodies, and public institutions International organizations (WHO, OECD, IMF, World Bank, etc.) Commercial and paid databases Industry associations, trade publications, and technical journals Company annual reports, investor presentations, press releases, and SEC filings Academic research papers, patents, and scientific literature Previous market research publications and syndicated reports These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights
Most GLP-1 patients who notice shedding are experiencing something called telogen effluvium
